Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.

Richard S P HuangDavid P CarboneGerald LiAlexa SchrockRyon P GrafLiangliang ZhangKarthikeyan MurugesanJeffrey S RossKhaled TolbaJacob SandsGeoffrey R OxnardDavid Spigel

Published in: Journal for immunotherapy of cancer (2023)

This study provides evidence that higher TMB cut-offs, such as 20 muts/Mb, can identify patients with prolonged benefit from ICPI. TMB ≥20 muts/Mb is a potential biomarker that may identify patients in whom an ICPI without chemo could be considered, even in the setting of lower PD-L1 levels. Prospective validation of these findings could increase access to chemo-sparing regimens for the first-line treatment of advanced NSCLC.

Keyphrases

small cell lung cancer
newly diagnosed
end stage renal disease
photodynamic therapy
ejection fraction
advanced non small cell lung cancer
peritoneal dialysis
drug delivery
brain metastases
patient reported